Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression

Many cancers express Fas ligand (FasL/CD95L) in vivo, and can kill lymphoid cells by Fas-mediated apoptosis in vitro. However, overexpression of recombinant FasL in murine tumour allografts revealed a potential antitumour effect of FasL, via recruitment of neutrophils. Transforming growth factor-β1...

Descripción completa

Detalles Bibliográficos
Autores principales: Houston, A, Bennett, M W, O'Sullivan, G C, Shanahan, F, O'Connell, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394303/
https://www.ncbi.nlm.nih.gov/pubmed/14520470
http://dx.doi.org/10.1038/sj.bjc.6601240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394303/
https://www.ncbi.nlm.nih.gov/pubmed/14520470
http://dx.doi.org/10.1038/sj.bjc.6601240

Ejemplares similares